MX2017002512A - Molecula terapeutica antiplaquetaria y anticoagulante que comprende heparina conjugada a una proteina de plasma. - Google Patents

Molecula terapeutica antiplaquetaria y anticoagulante que comprende heparina conjugada a una proteina de plasma.

Info

Publication number
MX2017002512A
MX2017002512A MX2017002512A MX2017002512A MX2017002512A MX 2017002512 A MX2017002512 A MX 2017002512A MX 2017002512 A MX2017002512 A MX 2017002512A MX 2017002512 A MX2017002512 A MX 2017002512A MX 2017002512 A MX2017002512 A MX 2017002512A
Authority
MX
Mexico
Prior art keywords
therapeutic
plasma protein
apac
heparin conjugated
molecule
Prior art date
Application number
MX2017002512A
Other languages
English (en)
Inventor
Lassila Riitta
Original Assignee
Aplagon Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aplagon Oy filed Critical Aplagon Oy
Publication of MX2017002512A publication Critical patent/MX2017002512A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A61K38/385—Serum albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Materials Engineering (AREA)
  • Toxicology (AREA)
  • Polymers & Plastics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención se refiere a una molécula antitrombótica que tiene tanto actividad antiplaquetaria como anticoagulante (APAC); su uso como medicamento; su configuración selectiva y uso como anticoagulante e inhibidor de la agregación plaquetaria, o su configuración y uso selectivo, predominantemente, como cualquiera de un anticoagulante o un inhibidor de la agregación plaquetaria; y un método para su producción.
MX2017002512A 2014-08-26 2015-08-24 Molecula terapeutica antiplaquetaria y anticoagulante que comprende heparina conjugada a una proteina de plasma. MX2017002512A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1415062.7A GB201415062D0 (en) 2014-08-26 2014-08-26 Therapeutic
GBGB1510637.0A GB201510637D0 (en) 2014-08-26 2015-06-17 Therapeutic
PCT/EP2015/069327 WO2016030316A1 (en) 2014-08-26 2015-08-24 Therapeutic apac molecule comprising heparin conjugated to a plasma protein

Publications (1)

Publication Number Publication Date
MX2017002512A true MX2017002512A (es) 2017-05-23

Family

ID=51727031

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017002512A MX2017002512A (es) 2014-08-26 2015-08-24 Molecula terapeutica antiplaquetaria y anticoagulante que comprende heparina conjugada a una proteina de plasma.

Country Status (16)

Country Link
US (2) US11446361B2 (es)
EP (1) EP3185907B1 (es)
JP (2) JP6714577B2 (es)
KR (1) KR102469621B1 (es)
CN (1) CN106794257B (es)
AU (1) AU2015308969B2 (es)
BR (1) BR112017003876A2 (es)
CA (1) CA2957316C (es)
DK (1) DK3185907T3 (es)
ES (1) ES2700883T3 (es)
GB (2) GB201415062D0 (es)
MX (1) MX2017002512A (es)
PL (1) PL3185907T3 (es)
RU (1) RU2714112C2 (es)
SG (1) SG11201700830WA (es)
WO (1) WO2016030316A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10722557B2 (en) * 2016-07-14 2020-07-28 Virginia Commonwealth University Treatment of ischemia reperfusion injury using alpha-2 macroglobulin
GB202006960D0 (en) 2020-05-12 2020-06-24 Aplagon Oy Therapeutic
CN113304332A (zh) * 2021-05-12 2021-08-27 广东顺德工业设计研究院(广东顺德创新设计研究院) 一种抗凝血涂层及其制备方法
WO2023152291A1 (en) * 2022-02-11 2023-08-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for treating thrombotic disorders

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4526714A (en) * 1982-12-13 1985-07-02 Cordis Europa N.V. Conjugates of anticoagulant and protein
NL188622C (nl) 1981-12-15 1992-08-17 Cordis Europ Werkwijze ter verbetering van de bloedcompatibiliteit van een materiaaloppervlak door bekleding daarvan met een heparine of heparine-analoga en een eiwit houdende film, alsmede voorwerp, omvattende een oppervlak met verbeterde bloedcompatibiliteit verkregen onder toepassing van een op het oppervlak aangebrachte heparine of heparine-analoga en een eiwit houdende film.
US6562781B1 (en) 1995-11-30 2003-05-13 Hamilton Civic Hospitals Research Development Inc. Glycosaminoglycan-antithrombin III/heparin cofactor II conjugates
US7045585B2 (en) * 1995-11-30 2006-05-16 Hamilton Civic Hospital Research Development Inc. Methods of coating a device using anti-thrombin heparin
US6491965B1 (en) * 1995-11-30 2002-12-10 Hamilton Civic Hospitals Research Development, Inc. Medical device comprising glycosaminoglycan-antithrombin III/heparin cofactor II conjugates
FI974321A0 (fi) * 1997-11-25 1997-11-25 Jenny Ja Antti Wihurin Rahasto Multipel heparinglykosaminoglykan och en proteoglykan innehaollande dessa
CA2634495A1 (en) * 2005-12-22 2007-06-28 Conjuchem Biotechnologies Inc. Process for the production of preformed conjugates of albumin and a therapeutic agent
CA2668347C (en) * 2006-11-07 2017-06-20 Genentech, Inc. Tissue plasminogen activator variant uses
FR2912408A1 (fr) * 2007-02-14 2008-08-15 Sanofi Aventis Sa Heparine comprenant au moins une liaison covalente avec la biotine ou un derive de la biotine,leur procede de preparation,leur utilisation
RU2366441C2 (ru) * 2007-08-03 2009-09-10 Государственное учреждение гематологический научный центр Российской академии медицинских наук (ГУ ГНЦ РАМН) Антикоагулянтное средство на основе биологически активного комплекса из коры кедра сибирского
KR100971271B1 (ko) 2008-04-28 2010-07-20 한양대학교 산학협력단 헤파린이 결합된 피브린젤, 그 제조방법 및 키트
US9925270B2 (en) 2011-11-28 2018-03-27 The Regents Of The University Of California bFGF-polymer conjugates, methods for making the same and applications thereof
EP2793909B1 (en) 2011-12-22 2020-12-09 Corline Biomedical AB An aqueous solution comprising a macromolecular conjugate of heparin for the treatment of blood vessels
GB2556531A (en) * 2015-06-11 2018-05-30 Attwill Medical Solutions Inc Medical devices, systems, and methods utilizing antithrombin-heparin compositions

Also Published As

Publication number Publication date
ES2700883T3 (es) 2019-02-19
EP3185907A1 (en) 2017-07-05
DK3185907T3 (da) 2019-01-02
JP6894993B2 (ja) 2021-06-30
EP3185907B1 (en) 2018-10-03
RU2017107227A (ru) 2018-10-01
BR112017003876A2 (pt) 2018-01-23
GB201415062D0 (en) 2014-10-08
US20220339264A1 (en) 2022-10-27
JP2017526664A (ja) 2017-09-14
WO2016030316A1 (en) 2016-03-03
RU2714112C2 (ru) 2020-02-11
PL3185907T3 (pl) 2019-05-31
RU2017107227A3 (es) 2019-02-28
JP6714577B2 (ja) 2020-06-24
NZ728689A (en) 2023-10-27
CA2957316C (en) 2022-07-12
GB201510637D0 (en) 2015-07-29
AU2015308969B2 (en) 2020-05-21
CN106794257A (zh) 2017-05-31
KR20170044192A (ko) 2017-04-24
US11446361B2 (en) 2022-09-20
CA2957316A1 (en) 2016-03-03
US20170266299A1 (en) 2017-09-21
SG11201700830WA (en) 2017-03-30
JP2020111597A (ja) 2020-07-27
CN106794257B (zh) 2020-03-13
KR102469621B1 (ko) 2022-11-21
AU2015308969A1 (en) 2017-03-02

Similar Documents

Publication Publication Date Title
EP3356595A4 (en) METHODS OF PRODUCING NANOCELLULOSE, AND NANOCELLULOSE COMPOSITIONS PRODUCED THEREFROM
EA201692105A1 (ru) Новые пиразолопиримидиновые производные и их применение в качестве ингибиторов malt1
EP3297637A4 (en) BENZOL-1,3,5-TRICARBOXAMIDE DERIVATIVES AND USES THEREOF
EP3245885A4 (en) Non-combustible flavor inhaler, flavor source unit, and method for manufacturing non-combustible flavor inhaler member
EP3592746A4 (en) TYK2 INHIBITORS, THEIR USES AND THEIR PRODUCTION PROCESSES
EA201791133A1 (ru) Ингибиторы erk
DK3513809T3 (da) Medicinsk sammensætning, som omfatter tivozanib
AU2016316202A8 (en) Molecular constructs for preventing the formation of blood clot and/or treating thrombosis
DK3227297T3 (da) 4,6-substitueret-pyrazolo[1,5-a]pyraziner som janus kinase-inhibitorer
MX2019004500A (es) Terapia de combinación para la inhibición de componente de complemeto (c3).
EP3302325A4 (en) CRYOABLATION CATHETER WITH AN ELLIPTICALLY SHAPED TREATMENT PROFILE
EP3490566A4 (en) DETERMINED (2S) -N - [(1S)] - 1-CYANO-2-PHENYLETHYL-1,4-OXAZEPAN-2-CARBOXAMIDES FOR TREATING BRONCHIEKTASIS
WO2016046156A8 (de) Substituierte oxopyridin-derivate
MA40457A (fr) Combinaison de médicaments pour traiter le myélome multiple
MX2017002512A (es) Molecula terapeutica antiplaquetaria y anticoagulante que comprende heparina conjugada a una proteina de plasma.
MX2018002416A (es) Derivados de 1,7-diaril-1,6-heptadien-3,5-diona, procedimiento para la preparación y uso de los mismos.
EP3559253A4 (en) BLOOD PROFILING WITH PROTEASE INHIBITORS
EP3308781A4 (en) BLOOD PRESSURE CENTER
WO2017096303A3 (en) Cerdulatinib for treating hematological cancers
EP3258945A4 (en) Modified blood clots
EP3266361A4 (en) SPRAY ARRANGEMENT FOR DISHWASHER AND DISHWASHER
EP3708161A4 (en) MITOCHONDRIAL DYSFUNCTION IMPROVEMENT AGENTS, PROPHYLACTIC OR THERAPEUTIC FOR DISEASES OR SYMPTOMS CAUSED BY MITOCHONDRIAL DYSFUNCTION AND USES THEREFORE
EP3378922A4 (en) TOXIC AND ECOLOGICAL GAS-REDUCING IGNITION COAL AND MANUFACTURING METHOD THEREOF
EP3298161A4 (en) METHODS, SYSTEMS AND COMPOSITIONS FOR DETERMINING THE FORMATION OF BLOOD CLOTHS AND USES THEREOF
EP4268891A3 (en) Compound for use in methods for treatment of polycystic kidney disease